Driving an older vehicle is often a smart financial decision, as theyre typically more affordable to buy and insure. But an older vehiclecould alsomake you a target for car thieves.
The National Insurance Crime Bureau recently released its annual Hot Wheels report, which identifies the 10 most-stolen vehicles in 2016 in the United States according to vehicle theft data.
Honda Accords and Civics are at the top of the list, with nearly 100,000 thefts combined. And older models of those cars are the most-targeted by thieves:
VehicleTotal thefts in 2016Model year most stolen1. Honda Accord50,42719972. Honda Civic49,54719983. Ford pickup32,72120064. Chevy pickup31,23820045. Toyota Camry16,73220166. Nissan Altima12,22120157. Dodge pickup12,12820018. Toyota Corolla11,98920159. Chevy Impala9,749200810. Jeep Cherokee/Grand Cherokee9,2452000
Best Insurance Stocks To Own For 2018: Boeing Company (BA)
- [By Paul Ausick]
We’re all about to find out whether trade wars are good and easy to win. If you’re keeping score at home, just keep an eye on the share price of Boeing Co. (NYSE: BA). That’ll give you a rough idea of how the war’s going.
- [By Todd Shriber, ETF Professor]
Since DFEN's index is a cap-weighted benchmark, it is good news for this leveraged ETF when big-name defense stocks such as Dow components Boeing Co. (NYSE: BA) and United Technologies Inc. (NYSE: UTX) rally. Good news for DFEN: Boeing and United Technologies are two of the 16 Dow stocks with year-to-date gains of at least 16 percent.
- [By WWW.KIPLINGER.COM]
Its in fashion to worry about Boeing Co. (BA), but the company isnt that troubled. Boeing beat analysts profit estimate over the summer and the cash-flow picture continued to strengthen.
Best Insurance Stocks To Own For 2018: CubeSmart(CUBE)
- [By Shane Hupp]
DigiCube (CUBE) uses the hashing algorithm. It launched on March 12th, 2016. DigiCube’s total supply is 2,429,126,009 coins. DigiCube’s official Twitter account is @PurePoS. DigiCube’s official website is www.freestaking.com.
Best Insurance Stocks To Own For 2018: Syndax Pharmaceuticals, Inc. (SNDX)
- [By Lisa Levin]
Shares of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) got a boost, shooting up 32 percent to $12.40 after the company reported the advancement of ENCORE 601 in non-small cell lung cancer patients with disease progression on or after PD-1 therapies.
- [By Chris Lange]
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is watching its shares make a handy gain on Wednesday after the firm reported a key agreement. Essentially, the company announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
- [By Logan Wallace]
Several institutional investors have recently bought and sold shares of the company. BVF Inc. IL acquired a new position in shares of Syndax Pharmaceuticals during the 4th quarter worth about $28,326,000. Millennium Management LLC grew its position in shares of Syndax Pharmaceuticals by 18.9% during the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock worth $4,525,000 after buying an additional 82,256 shares during the period. Geode Capital Management LLC grew its position in shares of Syndax Pharmaceuticals by 17.4% during the 4th quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock worth $1,344,000 after buying an additional 22,803 shares during the period. Crestline Management LP grew its position in shares of Syndax Pharmaceuticals by 55.3% during the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock worth $728,000 after buying an additional 29,607 shares during the period. Finally, State Street Corp grew its position in shares of Syndax Pharmaceuticals by 32.8% during the 2nd quarter. State Street Corp now owns 81,327 shares of the company’s stock worth $1,137,000 after buying an additional 20,106 shares during the period. Institutional investors own 69.55% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Rating Lowered to D at TheStreet” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at www.tickerreport.com/banking-finance/3364448/syndax-pharmaceuticals-sndx-rating-lowered-to-d-at-thestreet.html.
About Syndax Pharmaceuticals